MedTrace Logo

Secondary Adjuvant Long Term Study With Arimidex

NCT00295620 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3484

Last updated 2019-10-02

Study results available
· View outcomes & findings →

Summary

The study assesses the effect of further 2 years vs further 5 years of adjuvant treatment with anastrozole after initial 5 years of adjuvant endocrine therapy.

Conditions

Interventions

DRUG

Anastrozole

1mg tablet daily

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Austria Medical Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-01
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00295620 on ClinicalTrials.gov